We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $13 · 3 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
IBRX and the BCG Shortage: Deals That Could Expand Demand - Yahoo Finance
IBRX and the BCG Shortage: Deals That Could Expand Demand Yahoo Finance
IBRX Stock Outlook After Q1 Results and a New FDA Review - Yahoo Finance
IBRX Stock Outlook After Q1 Results and a New FDA Review Yahoo Finance
ImmunityBio: Anktiva Explained and What Comes Next - Yahoo Finance
ImmunityBio: Anktiva Explained and What Comes Next Yahoo Finance
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200 - Yahoo Finance
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200 Yahoo Finance
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX) - Yahoo Finance
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX) Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $-0.08 | — | — | $49.2M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.15 | — | — | $16.52M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.53 | — | — | $7.19M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.4 | — | — | $1.09M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 21. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 20. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 06. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 04. 22. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 04. 08. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 03. 27. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,385,500 | $33.64B | 0.03% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,717,843 | $9.34B | 0.01% | — | New position |